Despite industry surprise at Borland's acquisition of Visigenics, the reaction from Wall Street was not favourable as share prices fell $1.50 on the announcement of the deal (see news story, page 28).
To continue reading this article...
Join CRN
- Enjoy full access to channelweb.co.uk - the UK’s top news source for the IT channel
- Gain the latest insights through market analysis and interviews with channel leaders
- Stay on top of key trends with the Insider weekly newsletter curated by CRN’s editor
- Be the first to hear about our industry leading events and awards programmes
Already a CRN member?